Plain-English translation of NCT06947473 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new treatment called umbilical cord blood CD19-BCMA CAR T cell therapy for three serious autoimmune diseases: lupus nephritis (a kidney disease caused by lupus), systemic sclerosis (a disease affecting skin and organs), and Sjögren's syndrome with pulmonary hypertension (dry eye/mouth disease combined with high blood pressure in the lungs). The treatment uses special immune cells grown from donated umbilical cord blood and trained to fight the disease-causing cells in your body.
Standard treatments don't work well enough for some patients with these three autoimmune diseases, leaving them with progressive organ damage and few options. This trial exists to see if this new cell-based therapy can be safe and effective for patients who haven't benefited from conventional medicines.
You likely qualify if…
You likely don't qualify if…
You will receive the umbilical cord blood immune cells through an infusion (injection into your vein). The study will closely monitor you for safety, especially during the first 28 days after treatment, which is when side effects are most likely to appear. You will have follow-up visits and blood tests to track how well the treatment is working and watch for any problems. The trial is enrolling about 45 to 54 patients total across all three conditions at a single hospital in Beijing.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
China